Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases

DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G., ÖZKAN C., BİÇER Ö. S., TEKİN M.

ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA, vol.51, no.1, pp.1-6, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1016/j.aott.2016.03.004
  • Journal Name: ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1-6
  • Keywords: Denosumab, Recurrence, Giant cell tumor, ARTERIAL EMBOLIZATION, POSTMENOPAUSAL WOMEN, ZOLEDRONIC ACID, OPEN-LABEL, EXPRESSION, METASTASES, CURETTAGE, RECURRENT, THERAPY
  • Çukurova University Affiliated: Yes

Abstract

Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclear factor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of GCT with denosumab and to assess adverse effect profile and recurrence rate.